Lawrence Klein, Oruka Therapeutics CEO
April 3, 2024 07:30 AM EDT
Financing
Startups
Deals

Apogee, Spyre founder launch­es its third biotech and heads straight to Nas­daq

Kyle LaHucik

Senior Reporter

Af­ter cre­at­ing an­ti­body mak­ers Apogee and Spyre, Paragon Ther­a­peu­tics is back with an­oth­er in­flam­ma­to­ry and im­mune dis­ease biotech, and the start­up is im­me­di­ate­ly go­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times